The field of research in bladder cancer has seen significant advances in recent years. Next-
generation sequencing has identified the genes most mutated in bladder cancer. This …

Background The distant metastasis is the primary cause of cancer morbidity and mortality for
bladder cancer (BLCA) paitents. All the recommended therapy for it largely depends on how …

Abstract Background Long non-coding RNAs (lncRNAs) are extensively intricate in the
tumorigenesis and metastasis of various cancer types. Nevertheless, the detailed molecular …

Abstract Background The PURE-01 study (NCT02736266) evaluated the use of
pembrolizumab before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC) …

Bladder cancer is a complex disease with variable prognosis. Recent investigations into the
molecular landscape of bladder cancer have revealed frequent genetic alterations and …

Background The prognostic management of bladder cancer (BLCA) remains a great
challenge for clinicians. Recently, bulk RNA-seq sequencing data have been used as a …

The recommended treatment for patients with high-risk non–muscle-invasive bladder cancer
(HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guérin (BCG) …

Purpose: There is an urgent need for biomarkers of radiation response in organ-sparing
therapies. Bladder preservation with trimodality therapy (TMT), consisting of transurethral …

Abstract Background Long noncoding (lnc) RNAs and glycolysis are both recognized as key
regulators of cancers. Some lncRNAs are also reportedly involved in regulating glycolysis …

Background Molecular subtyping of bladder cancer has revealed luminal tumors generally
have a more favourable prognosis. However, some aggressive forms of variant histology …